Health
Entresto’s effect ‘unclear’ in advanced chronic heart failure: study – Korea Biomedical Review
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard…
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard therapy for heart failure with reduced ejection fraction (HFrEF).
However, a recent study showed that the treatment did not…
Continue Reading
-
General24 hours agoThis isn’t progress, it’s punishment
-
General23 hours agoMitch Marsh inspires Australia to three-wicket win over New Zealand in third T20I
-
General22 hours agoNothing to see here *wink wink*
-
General20 hours agoNewcastle Jets defeat semi-professional Heidelberg United 3-1 to lift first Australia Cup